SQZ Biotechnologies

SQZ Biotechnologies FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of SQZ Biotechnologies (SQZB) as of Nov 3, 2026 is 104.05 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 105.80 % — a change of -1.65% (lower).

FCF Conversion

104.05 %

YoY

-1.65%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of SQZ Biotechnologies is 2023 104.05 % . FCF Conversion Rate (FCF/EBITDA) of SQZ Biotechnologies was 2022 105.80 % . It decreases by -1.65% lower compared to the previous year.

The SQZ Biotechnologies FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-97.82 USD
Jan 1, 2019
110.74 USD
Jan 1, 2020
87.74 USD
Jan 1, 2021
120.38 USD
Jan 1, 2022
105.80 USD
Jan 1, 2023
104.05 USD
The SQZ Biotechnologies FCF Conversion history
YEARFCF ConversionYoY
104.05 %-1.65%
105.80 %-12.11%
120.38 %+37.20%
87.74 %-20.76%
110.74 %-213.21%
-97.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SQZ Biotechnologies Stock analysis

What does SQZ Biotechnologies do? SQZ Biotechnologies Co. develops cell therapies for cancer, infectious diseases, and serious conditions through clinical-stage platforms. The company focuses on engineered antigen presentation to activate immune responses, with its SQZ Enhanced APC (eAPC) Platform generating tumor-specific CD8+ T cell activation for antitumor responses. The SQZ Activating Antigen Carrier (AAC) Platform uses red blood cells engineered with tumor antigens and adjuvants to induce in vivo antigen presentation, while the SQZ Tolerizing Antigen Carrier (TAC) Platform aims to establish immune tolerance via antigen-specific in vivo mechanisms. These platforms target oncology applications, with the eAPC and AAC candidates in clinical development. The company's revenue model relies on clinical development and partnerships for its cell therapy platforms. SQZ Biotechnologies Co. is a clinical-stage biotechnology firm, meaning it generates income through research and development funding, potential future licensing agreements, and partnerships with pharmaceutical companies. Its focus on oncology and immune activation positions it for collaboration with biopharma entities seeking to advance cell therapy technologies. The primary buyers of its technology are pharmaceutical companies interested in integrating these platforms into their therapeutic pipelines. SQZ Biotechnologies Co. targets the oncology segment for its cell therapy platforms, specifically focusing on tumor antigen-specific immune activation. The company's platforms are designed for patients with cancer, infectious diseases, and serious conditions, but its clinical-stage development is primarily directed at oncology applications. The SQZ eAPC and AAC platforms are in clinical development, with the company aiming to advance these candidates toward regulatory approval and commercialization. The TAC platform is also under development for immune tolerance applications, though it is not yet in clinical stages. SQZ Biotechnologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SQZ Biotechnologies stock

FCF Conversion Rate (FCF/EBITDA) of SQZ Biotechnologies is 104.05 % in 2023.

FCF Conversion Rate (FCF/EBITDA) of SQZ Biotechnologies changed from 105.80 % to 104.05 %, representing a -1.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) SQZ Biotechnologies since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s SQZ Biotechnologies with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — SQZ Biotechnologies

All Key Metrics — SQZ Biotechnologies